
|Videos|November 26, 2013
Episode 12 - Specialty Pharmacy's Role in CRPC
Advertisement
Episodes in this series

While discussing channel management in urology, Jeffrey D. Dunn, PharmD, MBA, introduces specialty pharmacy’s role.
Moderator Raoul S. Concepcion, MD, explains that the concept of pharmacy benefit is relatively new in the field of urology.
Dr Dunn and Michael Kolodziej, MD, explain their concerns about treatment expenses, care management, and the challenge for clinicians to select the specialty pharmacy of their choice.
Additionally, David Quinn, MD, explains why the administration of parenteral drugs through infusion centers has become a concern to clinicians.
Advertisement
Related to this article

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
5













